- Assessment
- Review
- Consultation
- 4Plan
Advanced targeted therapies for severe allergic and Type 2 inflammatory disease.
For selected patients with severe or uncontrolled disease, biologic therapies act on the specific inflammatory pathways that drive symptoms — offering precision where standard treatment has reached its limits.
Targeted therapies that interrupt a single inflammatory pathway — instead of suppressing the entire immune system.
Biologics are precision-engineered molecules — typically monoclonal antibodies — that bind a specific cytokine, receptor or immunoglobulin involved in chronic inflammation. In severe allergic and Type 2 inflammatory disease, this means blocking the very signals that sustain eosinophilic and allergic inflammation across the airway, sinuses, skin and gut.
Precision over suppression
Unlike systemic corticosteroids, which broadly suppress immunity, biologics neutralize a single cytokine or receptor that sustains chronic inflammation — sparing the rest of the immune system.
A shared inflammatory axis
IL-4, IL-5, IL-13, IgE and TSLP drive a common inflammatory program expressed across the airway, sinuses, skin, gut and esophagus — explaining why these conditions often coexist.
One disease, many biologies
Two patients with the same diagnosis may have different underlying biology. Biomarkers — eosinophils, IgE, FeNO, periostin — help map each patient to the pathway most likely driving their disease.
Different diagnoses. One shared inflammatory architecture.
These conditions are often interconnected through the same type 2 cytokines. Mapping the full inflammatory profile — not just a single diagnosis — guides precision therapy.
When standard treatment is no longer enough.
For many patients, chronic inflammation continues despite correctly prescribed therapy. Recognizing this pattern early is the entry point to advanced evaluation.
- Persistent symptoms despite maximal standard therapy
- Recurrent exacerbations or flares
- Repeated courses of oral corticosteroids
- Steroid dependence or cumulative toxicity
- Recurrent surgery (e.g. nasal polyposis)
- Chronic impairment of sleep, work or daily life
- Multiple coexisting type 2 conditions
- Incomplete response to escalated treatment
Biologic selection is individualized — guided by phenotype, biomarkers and disease burden.
A structured evaluation integrates multiple dimensions of disease. The goal is not to prescribe — it is to determine, with clinical rigor, whether a biologic is appropriate and which target is most likely to help.
Disease phenotype
- Allergic vs non-allergic
- Eosinophilic vs non-eosinophilic
- Early vs late-onset disease
Biomarker profile
- Blood eosinophils, total and specific IgE
- FeNO and inflammatory markers
- Periostin and emerging biomarkers
Disease burden
- Exacerbation frequency and severity
- OCS exposure and steroid dependence
- Lung function, imaging and validated control scores
Comorbidities & history
- Atopic multimorbidity across organ systems
- Prior treatment response and tolerability
- Age, pregnancy, vaccination and comorbid disease
A coordinated, phenotype-driven pathway — from assessment to longitudinal follow-up.
- Step 01
Structured digital assessment
Validated instruments capture symptoms, control, exacerbations and treatment history across all type 2 domains.
- Step 02
Virtual specialty evaluation
Detailed phenotyping, biomarker interpretation and review of prior studies — performed by the specialist, not by an algorithm.
- Step 03
Coordinated in-person evaluation
When indicated, a structured 48-hour in-person work-up: lung function, advanced biomarkers, imaging review and integrated strategy.
- Step 04
Personalized treatment planning
Phenotype-aligned recommendations on candidacy, sequencing and monitoring — shared with you and your treating physician.
- Step 05
Longitudinal follow-up
Structured response assessment, biomarker re-evaluation and treatment adjustment over time — continuity is part of the therapy.
What advanced therapy honestly involves.
Biologics are powerful, but they are not appropriate for every patient. Careful evaluation and continuity matter as much as the therapy itself.
- Biologics are not first-line therapy — they are reserved for selected patients after structured evaluation.
- Response varies between patients; meaningful benefit is typically assessed over months, not days.
- Treatment selection is individualized: phenotype, biomarkers, comorbidities and prior therapy all matter.
- Long-term monitoring — symptoms, biomarkers, exacerbations — is essential and part of the therapy itself.
- Final prescribing decisions remain with your treating physician. Our role is structured, specialist-level orientation.
Could a targeted therapy be right for you?
Begin with a structured 2-minute assessment. If your profile suggests advanced disease, we will guide you through specialty evaluation.